Compare KE Holdings Inc (BEKE) vs HCA Health Inc (HCA) Price & Performance

BEKE trades at $16.07, up 3.21% today, with a bullish technical signal and strong analyst consensus (91.67% buy ratings). Recent Q1 2026 earnings beat expectations with EPS of $0.20 versus $0.14 forecast, driven by cost controls and operational efficiency. Revenue for 2025 was $94.58 billion, with a net income margin of 3.76%, though cash flow from operations was negative $376.17 million.

The outlook is positive given earnings momentum and oversold conditions suggesting a potential reversal. Risks include reliance on China's property market and volatile cash flows. With high institutional support and improving profitability, the stock presents a growth opportunity amid market recovery prospects.

HCA Healthcare stock trades at $390.74, down 3.9% following a lowered 2026 profit outlook. The company maintains strong fundamentals with revenue growth to $75.6B in 2025 and consistent earnings beats, though technical indicators show bearish momentum. Recent news highlights challenges from payer mix shifts and rising uninsured patients, creating near-term headwinds despite long-term capacity expansion initiatives.

The stock presents a valuation opportunity with a P/E of 13.5x below industry averages, supported by analyst consensus target of $481.80. Key risks include execution on guidance and healthcare reimbursement pressures, but institutional sentiment remains positive with 63% buy ratings, suggesting potential recovery once near-term uncertainties resolve.